Agreements (Details 6) (USD $)	3 Months Ended								12 Months Ended						36 Months Ended			1 Months Ended					1 Months Ended			12 Months Ended		36 Months Ended								12 Months Ended					12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2014 Novartis	Jun. 30, 2013 Novartis	Jun. 30, 2012 Novartis	Oct. 31, 2013 Novartis	Oct. 31, 2013 Novartis Future Technological Improvements	Oct. 31, 2013 Novartis Research Services	Nov. 30, 2013 Novartis Right-to-test agreement	Oct. 31, 2013 Novartis Right-to-test agreement item	Mar. 31, 2013 Novartis Right-to-test agreement	Oct. 31, 2010 Novartis Right-to-test agreement	Jun. 30, 2014 Novartis Right-to-test agreement	Mar. 31, 2013 Novartis Right-to-test agreement Undisclosed Target item	Mar. 31, 2013 Novartis Right-to-test agreement Minimum Undisclosed Target	Mar. 31, 2013 Novartis Right-to-test agreement Exclusive license Undisclosed Target item	Jun. 30, 2014 Novartis Development and Commercialization License	Jun. 30, 2013 Novartis Development and Commercialization License	Oct. 31, 2013 Novartis Development and Commercialization License	Oct. 31, 2010 Novartis Development and Commercialization License	Nov. 30, 2013 Novartis Development and Commercialization License Maximum	Oct. 31, 2013 Novartis Development and Commercialization License Maximum	Mar. 31, 2013 Novartis Development and Commercialization License Maximum	Oct. 31, 2010 Novartis Development and Commercialization License Maximum	Mar. 31, 2013 Novartis Development and Commercialization License Development milestones	Oct. 31, 2010 Novartis Development and Commercialization License Development milestones	Jun. 30, 2014 Novartis Development and Commercialization License Development milestones Phase I clinical trial item	Mar. 31, 2013 Novartis Development and Commercialization License Regulatory milestones	Oct. 31, 2010 Novartis Development and Commercialization License Regulatory milestones	Mar. 31, 2013 Novartis Development and Commercialization License Sales milestones	Oct. 31, 2010 Novartis Development and Commercialization License Sales milestones	Jun. 30, 2014 Novartis Development and Commercialization License Exclusive license item
Collaborative Agreements disclosures
Term of agreement																					3 years
Term of extension of the agreement																			1 year
Payments for extension of agreement																			$ 5,000,000
Number of extension terms																			1
Additional term of extension of the agreement																			1 year
Payments received under collaboration agreement															60,200,000	4,500,000	710,000	1,000,000	1,000,000	1,000,000	45,000,000							55,000,000
License exercise fee, per license																													1,000,000
Potential milestone payments receivable																														199,500,000	199,500,000	199,500,000	199,500,000	22,500,000	22,500,000	5,000,000	77,000,000	77,000,000	100,000,000	100,000,000
Number of development and commercialization licenses taken																																				3					2
Number of pre-defined and related undisclosed targets																							2		1																2
License exercise fee, for the fourth license																						1,000,000
Agreed upon fee receivable on conversion of non-exclusive target to an exclusive target																								5,000,000
Payments received under collaboration agreement in connection with amended agreement																				3,500,000
Potential milestone payments under second option																																238,000,000		22,500,000			115,500,000		100,000,000
Amount of arrangement consideration included in license and milestone fees	305,000	305,000	25,678,000	13,167,000	855,000	22,010,000	429,000	933,000	39,455,000	24,227,000	9,161,000															17,200,000	11,100,000
Cumulative catch-up amount included in license and milestone fees																										1,000,000
Estimated utilization period after commercialization																										10 years
Discount rate (as a percent)																										16.00%
Estimated term of development and commercialization license																										25 years
Costs related to the research and development services	25,787,000	38,280,000	20,862,000	22,029,000	20,399,000	21,318,000	21,656,000	23,700,000	106,958,000	87,073,000	69,192,000	1,400,000	2,400,000	1,100,000
Costs related to clinical materials sold												$ 1,300,000	$ 134,000	$ 14,000